Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Matthew R Weir. (2019) Renal effects of sodium–glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. Postgraduate Medicine 131:6, pages 367-375.
Read now
Read now
Michael S. Kelly, Jelena Lewis, Ashley M. Huntsberry, Lauren Dea & Ivan Portillo. (2019) Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgraduate Medicine 131:1, pages 31-42.
Read now
Read now
Yajing Zhang, Huazhuo Ban, Runan Yu, Zhijian Wang & Dayong Zhang. (2018) Recent Progress of Sodium-Glucose Transporter 2 Inhibitors as Potential Antidiabetic Agents. Future Medicinal Chemistry 10:10, pages 1261-1276.
Read now
Read now
Articles from other publishers (17)
Chu-Hsuan Shiau, Li-Yun Tsau, Chih-Chin Kao, Yu-Ching Peng, Chyi-Huey Bai, Jeng‑Cheng Wu & Wen-Hsuan Hou. (2023) Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease: a systematic review and meta-analysis. International Urology and Nephrology 56:4, pages 1359-1381.
Crossref
Crossref
Mohamed Omer Mahgoub, Ifrah Ismail Ali, Jennifer O. Adeghate, Kornélia Tekes, Huba Kalász & Ernest A. Adeghate. (2023) An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus. International Journal of Molecular Sciences 24:11, pages 9328.
Crossref
Crossref
Apichaya Chanawong, Suriyon Uitrakul, Supatcha Incomenoy & Natnicha Poonchuay. (2023) Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study. Advances in Pharmacological and Pharmaceutical Sciences 2023, pages 1-9.
Crossref
Crossref
Ning Chen, Li-Kun Hu, Yue Sun, Jing Dong, Xi Chu, Ya-Ke Lu, Yu-Hong Liu, Lin-Lin Ma & Yu-Xiang Yan. (2023) Associations of waist-to-height ratio with the incidence of type 2 diabetes and mediation analysis: Two independent cohort studies. Obesity Research & Clinical Practice 17:1, pages 9-15.
Crossref
Crossref
Karen M. von Deneen & Malgorzata A. Garstka. (2022) Neuroimaging perspective in targeted treatment for type 2 diabetes melitus and sleep disorders. Intelligent Medicine 2:4, pages 209-220.
Crossref
Crossref
Lina T. Al Kury, Aya Abdoh, Kamel Ikbariah, Bassem Sadek & Mohamed Mahgoub. (2021) In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update. Molecules 27:1, pages 182.
Crossref
Crossref
Muhammad Shahzeb Khan & Muthiah Vaduganathan. (2020) What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?. Current Diabetes Reports 20:11.
Crossref
Crossref
Nicola Marrano, Giuseppina Biondi, Angelo Cignarelli, Sebastio Perrini, Luigi Laviola, Francesco Giorgino & Annalisa Natalicchio. (2020) Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?. Metabolism 110, pages 154304.
Crossref
Crossref
Gautam Phadke, Amit Kaushal, Dean R. Tolan, Kai Hahn, Thomas Jensen, Petter Bjornstad, Carlos Roncal-Jimenez, Ana Andres Hernando, Miguel A. Lanaspa, Mariam Priya Alexander, Aleksandra Kukla & Richard J. Johnson. (2020) Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report. American Journal of Kidney Diseases 76:1, pages 144-147.
Crossref
Crossref
Davida Kruger & Virginia Valentine. (2020) Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review. Diabetes Therapy 11:6, pages 1237-1250.
Crossref
Crossref
Javed Butler, Yehuda Handelsman, George Bakris & Subodh Verma. (2020) Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. European Journal of Heart Failure 22:4, pages 604-617.
Crossref
Crossref
Niki Katsiki & Filippos Triposkiadis. (2019) Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?. Current Vascular Pharmacology 17:4, pages 421-424.
Crossref
Crossref
Habib Yaribeygi, Alexandra E. Butler, Stephen L. Atkin, Niki Katsiki & Amirhossein Sahebkar. (2018) Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. Journal of Cellular Physiology 234:1, pages 223-230.
Crossref
Crossref
Shengbin Zhou, Yanan Duan, Jiang Wang, Jin Zhang, Haifeng Sun, Haowen Jiang, Zhanni Gu, Junhua Tong, Jingya Li, Jia Li & Hong Liu. (2017) Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5 H -thieno[3′,2’:3,4]pyrido[1,2- b ]isoquinolines as novel adenosine 5′-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes. European Journal of Medicinal Chemistry 140, pages 448-464.
Crossref
Crossref
Kai Hahn, Mehmet Kanbay, Miguel A. Lanaspa, Richard J. Johnson & A. Ahsan Ejaz. (2017) Serum uric acid and acute kidney injury: A mini review. Journal of Advanced Research 8:5, pages 529-536.
Crossref
Crossref
Hermann Koepsell. (2017) The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacology & Therapeutics 170, pages 148-165.
Crossref
Crossref
Angeliki M. Stamatouli & Silvio E. Inzucchi. (2016) Implications of the EMPA-REG Trial for Clinical Care and Research. Current Diabetes Reports 16:12.
Crossref
Crossref